Foster City, CA – According to filings with the U.S. Securities and Exchange Commission, TrueBinding is raising $50,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Dongxu Sun played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About TrueBinding
Founded in 2016, TrueBinding Inc. is a clinical stage biotherapeutic company creating new and exciting molecules for applications in neurodegenerative diseases (AD, PD, ALS), stroke, metabolic diseases, oncology and other disease areas with great unmet medical need. Based its proprietary Truebinding platform, TrueBinding has to date discovered over 6 novel drug targets and developed potentially game changing monoclonal antibody drugs.

To learn more about TrueBinding, visit http://www.truebinding.com/

Contact:
Dongxu Sun, President and Chief Executive Officer
650-847-1117
https://www.linkedin.com/in/dongxu-sun-96903057/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved